Potential role for estrogen replacement in the treatment of Alzheimer's dementia

American Journal of Medicine

Volumn 103, Issue 3 A, 1997, Pages 46S-50S

  Schneider, Lon S ^a   Farlow, Martin R ^c   Pogoda, Janice M ^b  

^a ROSS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; PLACEBO; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030873656     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00257-X     Document Type: Conference Paper

References (24)

1. Hefti F, Schneider LS. Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease. Psychiatr Devel. 4:1989;297-315.
2. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 271:1994;985-991.
3. Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer's disease. Lancet. 337:1991;989-992.
4. Farlow M, Gracon Si, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J. A 12-week, double-blind, placebo-controlled, parallel-group study of tacrine in patient with probable Alzheimer's disease. JAMA. 268:1992;2523-2529.
5. Davis KL, Thal LJ, Gamzu E, et al. Tacrine in patients with Alzheimer's disease: a doubleblind, placebo-controlled multicenter study. N Engl J Med. 327:1992;1253-1299.
6. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging. 15:(suppl 2):1994;S195-S197.
7. Fillit H, Weinreb H, Cholst I, Luine V, McEwen B, Amador R, Zabriskie J. Observations in a preliminary open trial of estradiol therapy for senile dementia - Alzheimer's type. Psychoneuroendocrinology. 11:1986;337-345.
8. Honjo H, Ogino Y, Naitoh K. In vivo effects by estrone sulfate on the central nervous system - senile dementia (Alzheimer's type). J Steroid Biochem. 34:1989;521-525.
9. Honjo H, Ogino Y, Tanaka K, et al. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: a placebo-controlled double blind study. J Jpn Menopause Soc. 1:1993;167-171.
10. Ohkura T, Isse K, Akazawa K, Hamamoto M, Yaoi Y, Hagino N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocrine J. 41:1994;361-371.
11. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 83:1994;979-983.
12. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med. 330:1994;1062-1071.
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadian E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology. 34:1984;939-944.
14. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
15. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr. 141:1984;1356-1364.
16. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 46:1580-1584.
17. Luine VN, Khylchevskaya R, McEwen BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 86:1975;293-306.
18. Josefsson E, Tarkowski A, Carlsten H. Anti-inflammatory properties of estrogen. Cell Immunol. 142:1992;67-78.
19. Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L. Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol. 106:1987;191-202.
20. McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease. Neurology. 42:1992;447-448.
21. Aisen PS, Davis KL. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Am J Psychiatr. 151:1994;1105-1113.
22. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol. 73:1989;759-766.
23. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphisms and Alzheimer's disease. Lancet. 342:1993;697-699.
24. Manolio TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation. 88:1993;2163-2171.